FUJIFILM Diosynth Biotechnologies, a CDMO for biologics, viral vaccines and viral vectors, is investing £400 million at its UK facility in Billingham, Teesside. The investment will more than double the site’s existing development and manufacturing footprint, creating the largest multi-modal biopharmaceutical manufacturing site in the UK, and is expected to create up to 350 highly-skilled jobs. The new facilities are expected to be operational by late 2023.
 
The new multi-modal campus will include two new state-of-the-art facilities (a viral gene therapy GMP facility and a GMP mammalian cell culture facility) and is part of a ¥90 Billion Yen global capital investment package initially outlined by FUJIFILM Corporation in June 2021.
 
The investment will add a new cell culture facility in the expanded Billingham campus and triple existing cell culture capacity capabilities at the site with the addition of 4×2,000L and 2x500L single use bioreactor production capabilities for the manufacture of both monoclonal and novel antibody treatments. This expansion will also include the addition of the company’s MaruX GMP continuous manufacturing platform to provide a differentiated connected and integrated production platform offering.
 
The investment package will also expand the viral vector and gene therapy services with dedicated process development capabilities and a commercial-scale viral gene therapy GMP facility, both located on the Billingham campus. This expansion will deliver a ten-fold increase in gene therapy production capabilities by FUJIFILM Diosynth Biotechnologies in the UK, and complementing its existing global footprint including sites in College Station, TX and Watertown, MA. The investment will also facilitate the expansion of existing capabilities in vaccine manufacturing, along with new capabilities including mRNA production.
 
FUJIFILM Diosynth Biotechnologies previously announced plans to expands its viral vector and gene therapy offerings in Darlington, UK, with process development labs and manufacturing capabilities to support the production of investigational use of gene therapies in early-stage clinical trials. The process development labs will begin operations, with GMP manufacturing services, starting in spring 2022.
 
Additionally, an expansion of the existing 5,000L GMP microbial production facilities at the Billingham campus will increase microbial fermentation capacity by almost two-thirds. The expansion will include over 20,000 sq. ft of modular downstream clean room space, including two primary recovery and refolding suites, two purification suites and a column packing room, and is designed to implement FUJIFILM Diosynth Biotechnologies’ SymphonX technology.
 
The expansion also includes quality control (QC) labs, office space and materials storage. This expansion will be operational by late 2023/early 2024.
 
“We all know that there has never been a more important time to invest in biopharmaceuticals – and £400 million, the largest investment in British biopharmaceutical manufacturing for decades, signals FUJIFILM Diosynth Biotechnologies’ intent to be able to offer multi-modal options to respond to our customers’ needs with flexibility and agility to help solve public health demands, and deliver the medicines and vaccines of tomorrow,” said Martin Meeson, Chief Executive Officer of FUJIFILM Diosynth Biotechnologies. “With a strong growing demand for microbial, cell culture and viral gene therapy services, we are adding the capacity and latest technologies within one campus to offer a range of modalities to build an offering that will deliver novel promising treatments to patients for years to come.”